Cancer is treated with a medication called bendamustine hydrochloride injection, particularly certain forms of leukaemia and lymphoma. It has bendamustine, an alkylating compound that kills cancer cells by preventing them from synthesising DNA.
1. Alkylating agents, such as bendamustine, are a class of chemotherapeutic drugs that attach to DNA and stop cancer cells from proliferating properly.
2. It is often used to treat a variety of non-Hodgkin lymphomas (NHL), including mantle cell lymphomas and indolent lymphomas.3
3. In addition, bendamustine is used to treat CLL, or chronic lymphocytic leukaemia.
4. Combination therapy: It is usually used in conjunction with other immunotherapies or chemotherapeutic medications to increase the efficacy of treatment.
5. Intravenous Infusion: Medical personnel often administer bendamustine hydrochloride injection intravenously.
1. Bone Marrow Suppression: Bendamustine may have an impact on the bone marrow, which could result in less blood cell synthesis, which could raise the risk of infection and cause bleeding issues as well as anaemia.
2. Vomiting and Nausea: Treatment-related gastrointestinal side effects, such as nausea, are possible.
3. Patients may feel weak or worn out while receiving treatment.
4. Reactions to Infusions: Some patients may encounter reactions to infusions, including fever, chills, and skin rashes.
5. Low Blood Pressure: Bendamustine occasionally results in low blood pressure.
6. Patients may infrequently experience allergic responses to bendamustine.
7. Secondary malignancies: Long-term Bendamustine use may raise the risk of developing secondary malignancies.
Before beginning Bendamustine Hydrochloride therapy, patients should talk to their doctor about any possible risks and side effects. The management of adverse effects and the safe and efficient use of this medicine can be achieved through routine monitoring and appropriate medical supervision during therapy.